Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Prestige Consumer Healthcare Inc., Harrow or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Prestige Consumer Healthcare Inc., Harrow and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Prestige Consumer Healthcare Inc., Harrow and Inc.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Latest Pharmaceuticals and Prestige Consumer Healthcare Inc., Harrow, Inc. Stock News

As of April 23, 2026, Prestige Consumer Healthcare Inc. had a $2.7 billion market capitalization, compared to the Pharmaceuticals median of $584.3 million. Prestige Consumer Healthcare Inc.’s stock is down 5.3% in 2026, up 0.6% in the previous five trading days and down 28% in the past year.

Currently, Prestige Consumer Healthcare Inc.’s price-earnings ratio is 15.2. Prestige Consumer Healthcare Inc.’s trailing 12-month revenue is $1.1 billion with a 16.9% net profit margin. Year-over-year quarterly sales growth most recently was -2.4%. Analysts expect adjusted earnings to reach $4.540 per share for the current fiscal year. Prestige Consumer Healthcare Inc. does not currently pay a dividend.

As of April 23, 2026, Harrow, Inc. had a $1.4 billion market cap, putting it in the 50th percentile of all stocks. Harrow, Inc.’s stock is down 21.3% in 2026, down 7.1% in the previous five trading days and up 69.14% in the past year.

Currently, Harrow, Inc. does not have a price-earnings ratio. Harrow, Inc.’s trailing 12-month revenue is $272.3 million with a -1.9% net profit margin. Year-over-year quarterly sales growth most recently was 33.4%. Analysts expect adjusted earnings to reach $0.710 per share for the current fiscal year. Harrow, Inc. does not currently pay a dividend.

How We Compare Prestige Consumer Healthcare Inc., Harrow and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Prestige Consumer Healthcare Inc., Harrow and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Prestige Consumer Healthcare Inc., Harrow and Inc.’s Quality Grades

Company	Ticker	Quality
Prestige Consumer Healthcare Inc.	PBH	B
Harrow, Inc.	HROW	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Prestige Consumer Healthcare Inc. has a Quality Score of 79, which is Strong. Harrow, Inc. has a Quality Score of 67, which is Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both Prestige Consumer Healthcare Inc., Harrow and Inc. have a grade of B. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

Prestige Consumer Healthcare Inc., Harrow and Inc.’s Momentum Grades

Company	Ticker	Momentum
Prestige Consumer Healthcare Inc.	PBH	F
Harrow, Inc.	HROW	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Prestige Consumer Healthcare Inc. has a Momentum Score of 18, which is Very Weak. Harrow, Inc. has a Momentum Score of 64, which is Strong.

The Momentum Grade Winner: Harrow, Inc.

As you can clearly see from the Momentum Grade breakdown above, Harrow, Inc. is considered to have stronger momentum compared to Prestige Consumer Healthcare Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Harrow, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Prestige Consumer Healthcare Inc., Harrow and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Prestige Consumer Healthcare Inc.	PBH	D
Harrow, Inc.	HROW	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Prestige Consumer Healthcare Inc. has a Earnings Estimate Score of 35, which is Negative. Harrow, Inc. has a Earnings Estimate Score of 63, which is Positive.

The Earnings Estimate Revisions Grade Winner: Harrow, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Harrow, Inc. has a better Earnings Estimate Revisions Grade than Prestige Consumer Healthcare Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Harrow, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Prestige Consumer Healthcare Inc., Harrow and Inc. Grades

In addition to Quality, Estimate Revisions and Momentum, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Prestige Consumer Healthcare Inc., Harrow and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Prestige Consumer Healthcare Inc., Harrow or Inc. Stock?

Overall, Prestige Consumer Healthcare Inc. stock has a Momentum Score of 18, Estimate Revisions Score of 35 and Quality Score of 79.

Harrow, Inc. stock has a Momentum Score of 64, Estimate Revisions Score of 63 and Quality Score of 67.

Comparing Prestige Consumer Healthcare Inc., Harrow and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.